Lief Therapeutics Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- Investors
-
12
Lief Therapeutics General Information
Description
Developer of a medical device designed to revolutionize at-home care for post-traumatic stress disorder, depression, and anxiety. The company's device teaches how to control the body's natural stress response through vibratory biofeedback exercises, enabling users to measure heart rate and breath with medical accuracy to control stress.
Contact Information
Website
www.lief.aiCorporate Office
- 2443 Fillmore Street
- Suite 380-6060
- San Francisco, CA 94115-1814
- United States
Corporate Office
- 2443 Fillmore Street
- Suite 380-6060
- San Francisco, CA 94115-1814
- United States
Lief Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 20-May-2024 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series 2) | 31-Dec-2022 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series 1) | 15-Jul-2021 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 01-Jun-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 01-Jul-2018 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 21-Mar-2017 | Completed | Generating Revenue | |||
| 3. Product Crowdfunding | 11-Jan-2017 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Dec-2016 | $370K | Completed | Generating Revenue | ||
| 1. Seed Round | 01-Oct-2015 | $370K | $370K | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Lief Therapeutics Comparisons
Industry
Financing
Details
Lief Therapeutics Competitors (2)
One of Lief Therapeutics’s 2 competitors is TouchPoint Solution, a Accelerator/Incubator Backed company based in Scottsdale, AZ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TouchPoint Solution | Accelerator/Incubator Backed | Scottsdale, AZ | ||||
| Apollo Neuroscience | Venture Capital-Backed | Pittsburgh, PA |
Lief Therapeutics Signals
Lief Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Elevation Capital (Canada) | Venture Capital | Minority | ||
| JLS Fund | Venture Capital | Minority | ||
| StartX (US) | Accelerator/Incubator | Minority | ||
| Ayuh Ventures | Venture Capital | Minority | ||
| Lionheart Ventures | Venture Capital | Minority |
Lief Therapeutics FAQs
-
When was Lief Therapeutics founded?
Lief Therapeutics was founded in 2012.
-
Where is Lief Therapeutics headquartered?
Lief Therapeutics is headquartered in San Francisco, CA.
-
What is the size of Lief Therapeutics?
Lief Therapeutics has 12 total employees.
-
What industry is Lief Therapeutics in?
Lief Therapeutics’s primary industry is Therapeutic Devices.
-
Is Lief Therapeutics a private or public company?
Lief Therapeutics is a Private company.
-
What is Lief Therapeutics’s current revenue?
The current revenue for Lief Therapeutics is .
-
How much funding has Lief Therapeutics raised over time?
Lief Therapeutics has raised $1.69M.
-
Who are Lief Therapeutics’s investors?
Elevation Capital (Canada), JLS Fund, StartX (US), Ayuh Ventures, and Lionheart Ventures are 5 of 12 investors who have invested in Lief Therapeutics.
-
Who are Lief Therapeutics’s competitors?
TouchPoint Solution and Apollo Neuroscience are competitors of Lief Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process